Super-Sized Medtech Rounds Scarce, But Growing

The median value of super-sized medtech financings hit a high of $100 million in 2015. Five companies closed on venture deals worth $50 million or more, and three of those five raised at least $100 million, according to Informa’s Strategic Transactions. (See Exhibit 1.) Combined, those 2015 deals had a total value of $551 million. By comparison in 2011, when the total raised by super-sized deals peaked, seven deals yielded $566 million, but none were worth ≥$100 million, and the median value per round was $65 million. In 2014 when the least was raised through super-raises, five rounds yielded $385 million, for a median value of a relatively low $56 million per deal.

These medtech numbers have all been dwarfed of course by biotech, which saw in 2015 a full year of huge venture financings. By early December, private biotechs closed 55 venture...